


ICARE Member Reports

- NIH Countermeasures Against Chemical Threats (**CounterACT**) Program
- To develop FDA-approved therapeutics and diagnostic technologies that will reduced mortality and morbidity during and after chemical emergency events

Chemical Nerve Agents

Seizure-Pathology Model



Therapeutic Approaches:

- Anticholinergics
- AChE Reactivators
- Anticonvulsants
- Neuroprotectants
- Single Antidote

LD50 of VX



ICARE Member Reports: CounterACT

- ***Major topics of interest in epilepsy research***
 - Anticonvulsant and Neuroprotectant Research & Development
 - Emergency Medical Intervention (Diagnosis & Treatment of Seizures)
 - Treatment of Refractory and Recurring Seizures

ICARE Member Reports: CounterACT

- *Types of research support or other activities*
 - Basic and translational research portfolio
 - Co-funding of RAMPART: a clinical trial on the pre-hospital use of IM midazolam in an autoinjector
 - Support for NINDS Anticonvulsant Screening Program (CounterACT Tract)
 - Development of a portable, field-deployable EEG device (3 prototypes being tested)

ICARE Member Reports: CounterACT

- *Resources available for shared use or other opportunities for collaboration*
 - Anticonvulsant Screening Program – U. Utah
 - CounterACT Preclinical Development Facility (SRI Int. – Menlo Park, CA)
 - US Army MRICD – Aberdeen, MD (Screening w/ nerve agents)
 - Battelle Labs - Columbus, OH (GLP Screening w/ nerve agents)

ICARE Member Reports: CounterACT

- *Priorities for future activities*
 - Translating basic discoveries made during first 5 years to clinic
 - Next generation anticonvulsants and neuroprotectants
 - Cast a wide net to capture potential lead compounds
 - Repositioning FDA-approved drugs